Axsome Therapeutics Inc (AXSM) Reports Robust Revenue Growth in Q4 and Full Year 2023
Net Product Revenue: Q4 revenue of $71.5 million and full-year revenue of $204.9 million, marking significant year-over-year growth.
Auvelity Sales: First full year of launch generates $130.1 million in net product sales.
Sunosi Growth: Achieves 17% and 67% year-over-year growth in Q4 and full-year sales, respectively.
R&D and SG&A Expenses: R&D expenses increased to $97.9 million, and SG&A expenses rose to $323.1 million for the full year.
Net Loss: Reported a net loss of $98.7 million for Q4 and $239.2 million for the full year.
Cash Position: Cash and cash equivalents totaled $386.2 million at the end of 2023.
Upcoming Milestones: Anticipated NDA submissions and Phase 3 trial results in 2024.
On February 20, 2024, Axsome Therapeutics Inc (NASDAQ:AXSM) released its 8-K filing, announcing financial results for the fourth quarter and full year of 2023. The clinical-stage biopharmaceutical company, which focuses on developing therapies for central nervous system (CNS) disorders, reported a substantial increase in net product revenue, with year-over-year growth of 193% for the fourth quarter and 309% for the full year.
Axsome's flagship products, Auvelity and Sunosi, were prescribed to over 100,000 patients combined, reflecting the company's successful commercial execution. Auvelity, launched in October 2022, generated $130.1 million in net product sales in its first full year. Sunosi also showed strong performance, with net product revenue reaching $74.8 million for the year.
The company's financial health is further evidenced by its robust cash position, with cash and cash equivalents totaling $386.2 million at the end of 2023. This strong liquidity is expected to fund operations into cash flow positivity, based on the current operating plan.
Financial Performance and Challenges
Despite the impressive revenue growth, Axsome faced increased expenses, with R&D costs rising to $97.9 million and SG&A expenses climbing to $323.1 million for the full year. These increases were primarily due to the advancement of clinical trials, commercialization activities for Auvelity and Sunosi, and organizational growth.
The company reported a net loss of $98.7 million, or $(2.08) per share, for the fourth quarter, and a net loss of $239.2 million, or $(5.27) per share, for the full year. These losses included significant non-cash charges such as stock-based compensation and acquisition-related contingent consideration expense.
Strategic Developments and Future Outlook
Axsome's CEO, Herriot Tabuteau, MD, highlighted the company's transformational year and its momentum going into 2024. The company anticipates submitting two New Drug Applications (NDAs) for migraine and fibromyalgia treatments and expects topline results from three Phase 3 trials in narcolepsy, Alzheimers disease agitation, and ADHD.
"2023 was a transformational year for Axsome, based on successful commercial execution as well as substantial pipeline advancement and expansion," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.
The company's pipeline includes five late-stage product candidates for 10 serious psychiatric and neurologic conditions. With the completion of enrollment for the SYMPHONY Phase 3 trial in narcolepsy, Axsome is on track to report topline results this quarter, marking a significant milestone for the company.
For value investors, Axsome's financial results demonstrate a company on the rise, with strong revenue growth and a promising pipeline that could lead to future profitability. The company's strategic investments in R&D and commercialization efforts are laying the groundwork for long-term success in the biotechnology industry.
For more detailed financial information and future updates on Axsome Therapeutics Inc (NASDAQ:AXSM), stay tuned to GuruFocus.com.
Explore the complete 8-K earnings release (here) from Axsome Therapeutics Inc for further details.
This article first appeared on GuruFocus.
